Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-06-04 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Lynparza reduced recurrence risk in breast cancer
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' (8046A) and a date/time stamp (04 June 2021, 22:00 BST), which are hallmarks of a Regulatory News Service announcement, typically used in the UK market. The content is a press release detailing positive Phase III trial results (OlympiA) for the drug Lynparza, including statistical data and quotes from executives and researchers. This format—a major corporate announcement released via a regulatory wire service—is characteristic of a general regulatory filing that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement released through the RNS system and covers significant corporate/product news, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2021-06-04 English
AstraZeneca appoints new Chief Financial Officer
Regulatory Filings Classification · 98% confidence The document is an official announcement from AstraZeneca PLC, identified by the RNS Number (7947A) and the date format typical of regulatory news services. The core content announces the appointment of a new Chief Financial Officer (Aradhana Sarin) and the transition of the outgoing CFO (Marc Dunoyer) into a new role, conditional on the closing of the Alexion acquisition. This type of announcement, detailing changes in senior leadership (CFO appointment/departure), directly corresponds to the 'Board/Management Information' category. It is not a full financial report (10-K or IR), an earnings release (ER), or a remuneration report (DEF 14A), although it contains a summary of remuneration for the new CFO. The primary purpose is management change notification. Therefore, the classification is MANG.
2021-06-04 English
425 Filing
Regulatory Filings
2021-06-04 English
425 Filing
Regulatory Filings
2021-06-04 English
Issuer Document
Capital/Financing Update Classification · 99% confidence The document is titled 'FINAL TERMS' and explicitly states, 'This document constitutes the Final Terms of the Notes described herein for the purposes of the UK Prospectus Regulation.' It details the terms of a specific debt issuance (EUR 800,000,000 0.375 per cent. Notes due 2029) under an existing Euro Medium Term Note Programme. This structure—Final Terms supplementing a Base Prospectus—is characteristic of securities offerings, specifically related to debt capital markets. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate category for documents detailing the final terms of a new bond issuance or financing activity, as opposed to a general regulatory filing (RNS) or a general report (10-K, IR).
2021-06-03 English
Regulatory Filings 2021
Regulatory Filings
2021-06-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.